These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14977846)

  • 1. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
    Semba T; Funahashi Y; Ono N; Yamamoto Y; Sugi NH; Asada M; Yoshimatsu K; Wakabayashi T
    Clin Cancer Res; 2004 Feb; 10(4):1430-8. PubMed ID: 14977846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
    Funahashi Y; Sugi NH; Semba T; Yamamoto Y; Hamaoka S; Tsukahara-Tamai N; Ozawa Y; Tsuruoka A; Nara K; Takahashi K; Okabe T; Kamata J; Owa T; Ueda N; Haneda T; Yonaga M; Yoshimatsu K; Wakabayashi T
    Cancer Res; 2002 Nov; 62(21):6116-23. PubMed ID: 12414636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
    Mita M; Kelly KR; Mita A; Ricart AD; Romero O; Tolcher A; Hook L; Okereke C; Krivelevich I; Rossignol DP; Giles FJ; Rowinsky EK; Takimoto C
    Clin Cancer Res; 2011 Jan; 17(1):193-200. PubMed ID: 21208908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
    Keizer RJ; Funahashi Y; Semba T; Wanders J; Beijnen JH; Schellens JH; Huitema AD
    AAPS J; 2011 Jun; 13(2):230-9. PubMed ID: 21387147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
    Milojkovic Kerklaan B; Slater S; Flynn M; Greystoke A; Witteveen PO; Megui-Roelvink M; de Vos F; Dean E; Reyderman L; Ottesen L; Ranson M; Lolkema MP; Plummer R; Kristeleit R; Evans TR; Schellens JH
    Invest New Drugs; 2016 Jun; 34(3):329-37. PubMed ID: 27039386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small-molecule protein ligand interface stabiliser E7820 induces differential cell line specific responses of integrin α2 expression.
    Hülskamp MD; Kronenberg D; Stange R
    BMC Cancer; 2021 May; 21(1):571. PubMed ID: 34006252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current status of combination therapies of angiogenesis inhibitors: vascular normalization activity of a novel angiogenesis inhibitor E7820].
    Semba T
    Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):4-8. PubMed ID: 23302941
    [No Abstract]   [Full Text] [Related]  

  • 9. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
    Chen HH; Zhou HJ; Wu GD; Lou XE
    Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
    Yeh CH; Peng HC; Yang RS; Huang TF
    Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
    Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
    Trikha M; Zhou Z; Nemeth JA; Chen Q; Sharp C; Emmell E; Giles-Komar J; Nakada MT
    Int J Cancer; 2004 Jun; 110(3):326-35. PubMed ID: 15095296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis.
    Hamma-Kourbali Y; Di Benedetto M; Ledoux D; Oudar O; Leroux Y; Lecouvey M; Kraemer M
    Biochem Biophys Res Commun; 2003 Oct; 310(3):816-23. PubMed ID: 14550277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.